AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05831917 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy: All patients were treated with Unity MRI Linac intensity modulated radiation therapy, daily imaging of MRI-IGRT and online target delineation, redesign, and total radiation dose: GTV 70Gy/33f, GTVLN 70Gy/33f, CTV 60Gy/33f, CTVLN 54Gy/33f, 5 days per week. Dose limit: The average dose to the upper, middle, and lower pharyngeal constrictor muscles is ≤ 40-50Gy, with oropharyngeal cancer requiring an average dose to the upper, middle, and lower pharyngeal constrictor muscles to be ≤ 50Gy and ≤ 20Gy; Lower pharyngeal cancer requires an average dose of ≤ 40Gy for the upper and middle pharyngeal constrictor muscles, and ≤ 50Gy for the lower pharyngeal constrictor muscles.~chemotherapy: cisplatin 75mg/m2, 21 days per cycle, a total of 3 cycles.
Study NCT05488340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBP-EC01 0.1 x IV dose
Description: Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.6mL of LBP-EC01 (approximately 1x10\^11 PFU) diluted in 0.4mL of Lactated Ringer's solution given on Days 1 through Day 3.
Study NCT05488340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBP-EC01 0.01x IV Dose
Description: Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.06 mL of LBP-EC01 (approximately 1x10\^10 PFU) diluted in 0.94 mL of Lactated Ringer's solution given on Days 1 through Day 3.
Study NCT05488340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBP-EC01 IV Infusion Dose
Description: Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous infusion dose of 6mL of LBP-EC01 (approximately 1x10\^12 PFU) diluted in 94 mL of Lactated Ringer's solution given over 2 hours on Days 1 through Day 3.
Study NCT05488340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose regimen selected from Part 1 of placebo (Tris buffer).
Study NCT05488340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBP-EC01
Description: Dose regimen selected from Part 1 of LBP-EC01 (1x10\^10 - 1x10\^13 PFU) per dose.
Study NCT05488340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMP/SMX
Description: TMP/SMX (160 mg trimethoprim and 800 mg sulfamethoxazole) given orally BID on Days 1 through 3.
Study NCT05488340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TMP/SMX
Description: TMP/SMX (160 mg trimethoprim and 800 mg sulfamethoxazole) given orally BID on Days 1 through 3.
Study NCT05268276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1-perineal ice-gel pad application
Description: For the study group Immediately after delivery (within 30 minutes to one hour after delivery), an ice gel pad will be applied to perineal trauma. each gel pad will have fixed standardized diameter (an approximately 5 cm width, 23 cm length, and 1.5 cm thickness) and approved by Egyptian ministry of health. It will be kept in the freezer for 45-60 minutes and will be removed when frozen. Then, it will be wrapped in a sterile pad and applied to cover the perineum and anal region.The investigator will provide a clear and concise information through oral and written instructions about the following; 1) The ice gel pad's purpose, benefits, anticipated effects and how to apply it, 2) Apply the ice gel pad on perineum after birth within 30 minutes to an hour, 3) Instruct the women to apply the ice gel pad for about 20 minutes every two hours during the first 24 hours postpartum only
Study NCT05268276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2-performance of pelvic floor exercises (Kegel exercises)
Description: women will receive instructions to practice pelvic floor exercises (Kegel exercises) and will be asked to perform these exercises from 6 hours postpartum and continue at home till one week. Before applying the technique, the investigator will teach the women how to recognize the accurate muscle, whereby she imagines holding passing gases or trying to stop the flow of urine midstream at the same time. The women will be taught to insert a clean finger into the vagina before practicing the exercises and if the women feeling pressure around her finger, she is on the right track, . The investigator will perform vaginal examination while the woman is doing the pelvic floor exercises (Kegel exercises) to ensure correct use of muscles. The investigator will instruct the women to continue contracting the muscles for about 5 seconds and then to loosen them for 5 seconds and repeat it for five times each set, perform at least five sets per day
Study NCT05268276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3- perineal warm compresses application
Description: women will be instructed to apply warm compresses on perineal trauma 48 hours postpartum at home. This will be done by using a clean pad soaked in warm water and squeezed to remove excess water then placed gently on the perineum, the warm compresses will be applied for 15 minutes three times per day (every 8 hours), and water in the bowl will be replaced with every application. Women will be asked to apply warm compresses on perineal trauma from 48 hours postpartum till one week.
Study NCT06274632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADELANTE
Description: A manualized problem-solving intervention that addresses barriers to viral suppression in Latinos with HIV. At the patient-level, CHWs use motivational interviewing to facilitate problem-solving skill development around attending HIV care and adherence and establish an individually tailored goal-setting plan. We target emotional well-being and self-management through a rapport with CHW and the integration of an HIV-centered telenovela to facilitate participant reflection on difficult topics for skill-building. The CHW will also link the participant to needed services.
Study NCT05004415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 (R07496998)
Description: Study participants will receive a single radiolabeled dose of 550 mg AT-527.
Study NCT06387342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Namodenoson 25mg
Description: oral capsule
Study NCT04915599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooral® mouth cooling device (MCD)
Description: Cooral® mouth cooling device (MCD) to prevent oral mucositis (QM) in patients undergoing radiation therapy for head and neck malignancies
Study NCT04680741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Addiction Pilot App behavior tracking
Description: a smartphone-based application (app) which is designed to monitor attendance at twelve-step facilitation meetings.
Study NCT06319664 — intervention group
Intervention type: PROCEDURE
Intervention: retrosigmoid approach (RSA)
Description: The skull base approach choice was fundamentally followed by the modified classification.
Study NCT06319664 — intervention group
Intervention type: PROCEDURE
Intervention: subtemporal transtentorial transpetrosal approach (STTA)
Description: The skull base approach choice was fundamentally followed by the modified classification.
Study NCT06319664 — intervention group
Intervention type: PROCEDURE
Intervention: extended pterional transtentorial approach (EPTA)
Description: The skull base approach choice was fundamentally followed by the modified classification.
Study NCT06319664 — intervention group
Intervention type: PROCEDURE
Intervention: pretemporal trancavernous anterior transpetrosal approach (PTCA)
Description: The skull base approach choice was fundamentally followed by the modified classification.
Study NCT06319664 — intervention group
Intervention type: PROCEDURE
Intervention: presigmoid combined supra-infratentorial approach (PCA)
Description: The skull base approach choice was fundamentally followed by the modified classification.
Study NCT06319664 — intervention group
Intervention type: PROCEDURE
Intervention: inoperable
Description: The skull base approach choice was fundamentally followed by the modified classification.
Study NCT04731051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ01
Description: HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization
Study NCT04731051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard of care (SOC) for COVID-19
Description: Standard of care (SOC) for COVID-19
Study NCT04731051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care (SOC) for COVID-19
Description: Standard of care (SOC) for COVID-19
Study NCT05046132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: Administered once daily via SC injection.
Study NCT05046132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin capsules via oral administration.
Study NCT05046132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Placebo capsules via oral administration.
Study NCT05046132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Placebo
Description: Placebo capsules via oral administration.
Study NCT05046132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SC Placebo
Description: Placebo via SC injection.
Study NCT04790773 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Amazon Alexa based voice recording patient education
Description: Amazon Alexa based voice recording of medication education material
Study NCT05292638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKDB-501A
Description: Intramuscular injection CKDB-501A
Study NCT05292638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox®
Description: Intramuscular injection Botox®
Study NCT05112861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 1.25 mg, intravitreal injection
Study NCT05859971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN mapping using technetium-99m +/- isosulfan blue dye
Description: The isosulfan blue dye injection will be performed by the participating surgeon in the operating room; as per standard of care, injection will be subareolar. Incisions will be planned based on the technetium-99m activity or at the lateral aspect of the pectoralis muscle, per usual care.
Study NCT05859971 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SLN mapping with ICG fluorescence using the Asimov Platform
Description: 2 ml (5 mg) of ICG solution will be injected intradermally in 1-4 injection sites in the lateral areolar region. After injection, gentle manual massage will be performed for 5 minutes. ICG imaging will be obtained prior to incision. After incision is made (following standard of care procedures), the axilla will be visualized using the Asimov Platform to assess for ICG-fluorescence in sentinel lymph nodes.
Study NCT05875350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraligamental local anesthetic injection
Description: The intraligamental technique was administered using ligajet intraligamentary jet injector (Micro Mega Company) containing Articaine hydrochloride 4% with adrenaline 1:200000 (ArtPharma Dent, inc, Egypt)
Study NCT06454734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy by radial device
Description: Patients will receive treatment by extracorporeal shock waves therapy (ESWT).
Study NCT06454734 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo extracorporeal shock wave therapy by radial device
Description: Patients will receive treatment sham extracorporeal shock waves.
Study NCT06454734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DLT
Description: Patients will receive treatment with decongestive lymphatic therapy (DLT: manual lymphatic drainage, compression)
Study NCT06454734 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: DLT
Description: Patients will receive treatment with decongestive lymphatic therapy (DLT: manual lymphatic drainage, compression)
Study NCT05001750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: long term prophylactic antibiotics (Nafcillin or Doxycycline)
Description: VRIs in patients who also receive a pre-procedural dose of antibiotics with continued dosing of antibiotics for the duration of the external ventricular drain IRB NUMBER: 2021-12680 IRB APPROVAL DATE: 06/14/2021 NOABX in EVD Study 3 (EVD).
Study NCT05300399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth app
Description: The local healthcare providers will be assigned to an intervention group receiving the mHealth app to be used in their daily practices or a control group.
Study NCT04867291 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pizza
Description: Portion equivalent to 200 µg of iodine (half a pizza), consumed with \~450mL of water.
Study NCT04867291 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seaweed Sheets
Description: Portion equivalent to 200 µg of iodine (\~10g), consumed with two slices of white bread and \~450mL of water.
Study NCT04867291 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seaweed Powder
Description: Portion equivalent to 200 µg of iodine (1 capsule), consumed with two slices of white bread and \~450mL of water.
Study NCT04867291 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium iodide
Description: Portion equivalent to 200 µg of iodine (1.3 tablets), consumed with two slices of white bread and \~450mL of water.
Study NCT06425068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exposure of the patient to a novel air mattress.
Description: see information provided in the Arms section (experimental)
Study NCT06425068 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exposure of the patient to a conventional foam mattress.
Description: see information provided in the Arms section (active comparator)
Study NCT06273657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medisinstart
Description: Medisinstart is a counseling service in pharmacies where patients who start taking a new medicine receive two follow-up consultations with a pharmacist.
Study NCT06231199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gastrocnemius release
Description: The patient will be prone to lying and the therapist will stand at the side of the patient's leg. The therapist uses both hands in cross-hand pattern (Figure 10a and 10b). Myofascial Release will be performed for 20 repetitions, then gastrocnemius release by foam roller;This involved long sitting, with the affected leg will be extended on the foam roller and foot relaxed. The non-affected leg will be flexed at knee so that the foot will be rested on the floor. The participants will be instructed to use their arms and non_affected foot to propel their body back and forth from the popliteal fossa to Achilles tendon in continuous motion. then patients perform plantar fascia realise from standing by foam roller
Study NCT06231199 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: the patients will receive conventional treatment in the form of ultrasound therapy (continuous mode/1MHZ) followed by plantar fascia stretch and inctruction
Study NCT06231199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: the patients will receive conventional treatment in the form of ultrasound therapy (continuous mode/1MHZ) followed by plantar fascia stretch and inctruction
Study NCT04961372 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: PHQ9 Depression Scale for evaluating depression, GAD7 Anxiety Score for evaluating anxiety, WSAS Score for evaluating Work and Social Adjustment
Study NCT04955119 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fusion imaging contrast-enhanced ultrasound
Description: Fusion imaging contrast-enhanced ultrasound will be performed for patients with invisible lesion at conventional ultrasound.~Drug: SonoVue
Study NCT04925739 — intervention group
Intervention type: OTHER
Intervention: Self-questionnaire on the comfort and general appreciation of a nasal mask
Description: Self-questionnaire on the comfort and general appreciation of a nasal mask after 30 days of use
Study NCT04925739 — intervention group
Intervention type: OTHER
Intervention: Self-questionnaire on the appearance of CPAP side effects related to the mask
Description: Self-questionnaire on the appearance of CPAP side effects related to the mask (air leaks, injury to the nasal bridge, etc.) after 30 days of use
Study NCT04925739 — intervention group
Intervention type: OTHER
Intervention: Self-questionnaire on the patient's appreciation of the mask headgear,
Description: Self-questionnaire NOSE (Nasal Obstruction Symptom Evaluation) on the patient's appreciation of the mask headgear, which includes indications to help with the installation in the form of graduated markers, as well as the appreciation of the general aesthetics of the mask, after 30 days of use.
Study NCT04925739 — intervention group
Intervention type: OTHER
Intervention: Self-questionnaire NOSE on the discomfort caused by the nasal obstruction
Description: Self-questionnaire NOSE on the discomfort caused by the nasal obstruction reported by the patient, after 30 days of use, compared to the inclusion.
Study NCT04925739 — intervention group
Intervention type: OTHER
Intervention: Self-questionnaire Epworth on the daytime sleepiness
Description: Self-questionnaire Epworth on the daytime sleepiness of the patient, after 30 days of treatment, compared to the inclusion.~To study the parameters of the CPAP treatment.
Study NCT04925739 — intervention group
Intervention type: OTHER
Intervention: To study the CPAP compliance
Description: To collect the treatment compliance through telemonitoring of the data recorded by the CPAP machine, during the 30 days of treatment.
Study NCT05349734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: overbody blanket
Description: applying overbody blanket with forced-air blower set to 43℃
Study NCT05349734 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: underbody blanket
Description: applying underbody blanket with forced-air blower set to 43℃
Study NCT05445609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLP-encapsulated TLR9 Agonist CMP-001,
Description: Given SC or IT
Study NCT05445609 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT05787834 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care
Study NCT05787834 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Wear accelerometer
Study NCT05787834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear accelerometer
Study NCT05787834 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Muscle Training
Description: Undergo RMT
Study NCT05787834 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Training
Description: Undergo RMT
Study NCT05787834 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05787834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT04925739 — intervention group
Intervention type: OTHER
Intervention: To study the unintentional leakage
Description: To collect the unintentional leakage estimated by the CPAP machine, during the 30 days of treatment.
Study NCT04925739 — intervention group
Intervention type: OTHER
Intervention: To study the therapeutic pressures of CPAP
Description: To collect the therapeutic pressures of CPAP, during the 30 days of treatment.
Study NCT05270551 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL Reconstruction
Description: All participants will do ACL reconstruction with and without Augmentation and will receive Accelerated rehabilitation program
Study NCT05117372 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment with immunotherapy and diffuse infiltrative lung disease
Description: Patients treated with with immunotherapy and developing diffuse infiltrative lung disease
Study NCT05117372 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Patients requiring carcinologic lobectomy
Description: Patients requiring carcinologic lobectomy
Study NCT06060223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teach Back Method
Description: Training and consultancy services based on the teach-back method will be provided to individuals in the training group using the Heart Failure Training Guide in the form of 3 follow-ups in the cardiology clinic and telephone counseling. Telephone interviews were conducted by the researcher in the first week after discharge, it will be held in the first month and 3rd month. In addition, patients will receive counseling by calling the researcher if necessary.
Study NCT06553417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aqua posae and microresyl
Description: * This intervention involves the use of two topical products:~  * Aqua posae - a moisturizing agent~ * Microresyl - an active ingredient with potential therapeutic effects~* Subjects in Group A will be instructed to apply these two products (aqua posae and microresyl) twice daily to the upper and lower limbs, including both lesional and non-lesional areas of the skin.~The use of these interventions will be evaluated over a 12-week period, with assessments of Transepidermal Water Loss (TEWL), skin hydration, skin pH, index scoring of atopic dermatitis (SCORAD), erythema area severity index (EASI), pruritus visual analogue scale (PVAS), quality of life (DLQI), and any adverse effects.